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CASE REPORT
Erythromelalgia and Livedo Reticularis in a Patient with 
Essential Thrombocythemia, Acquired von Willebrand 
Disease, and Elevated Anti-Phospholipid Antibodies
Thilo Gambichler, M.D., Rebecca Matip, M.D.
Department of Dermatology, Ruhr-University Bochum, Bochum, Germany
Essential thrombocythemia (ET) is a clonal stem cell disease 
characterized by isolated thrombocytosis and thrombo-
hemorrhagic complications. We describe an unusual case of 
ET primarly presenting with skin symptoms including 
erythromelalgia and livedo reticularis (racemosa-type). 
Persistent thrombocytosis, bone marrow findings, JAK2 gene 
mutation, and markedly decreased ristocetin-cofactor acti-
vity were consistent with the diagnosis of ET and acquired 
von Willebrand disease. Elevated antiphospholipid anti-
bodies were also found. The present case highlights the 
complex nature and diagnostic challenge of myelopro-
liferative disorders such as ET, which can involve multiple 
organ systems and often shows a variety of microvascular 
complications, coagulation anomalies, and autoimmune 
phenomena. (Ann Dermatol 24(2) 214∼217, 2012)
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INTRODUCTION
Essential thrombocythemia (ET) is a clonal stem cell 
disease characterized by isolated thrombocytosis and 
thrombohemorrhagic complications. ET shares phenotypic 
and pathogenetic similarities with other myeloproliferative 
disorders (MPD), in particular polycythemia vera and 
primary myelofibrosis. The clinical presentation of ET is 
dominated by a predisposition to vascular occlusive 
events and hemorrhages. Vascular occlusive events include 
major thrombotic events involving the cerebrovascular, 
coronary, and peripheral arterial circulation. Deep vein 
thrombosis also represents a potentially serious and even-
tually life-threatening event. However, vascular occlusive 
events can also occur in the micro-vessels where they 
cause a wide range of clinical symptoms secondary to a 
transitory suspension of the circulation. They are caused 
by platelet-mediated transient occlusive thrombosis in the 
end-arterial circulation
1-3. Aspirin-sensitive erythromelalgia 
is one of the most common microvascular disorders in 
ET
4,5.
  Livedo reticularis, a characteristic feature of the 
antiphospholipid syndrome and Sneddon syndrome, has 
sporadically been observed in ET
6,7. We here describe an 
unusual case of ET primarly presenting with skin symp-
toms.
CASE REPORT
A 40-year-old man presented to our department because 
of painful skin lesions under both feet. Apart from diatetes 
mellitus type I and cigarette smoking, the medical history 
was unremarkable. However, the patient reported in-
creasing B-symptoms such as night sweats and an 11-kg 
weight loss. On examination, there were violeceous 
patches on the lateral side of the soles (right＞left; Fig. 1) Complex Presentation of Essential Thrombocythemia
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Fig. 1. Erythromelalgia under the right foot of a patient with 
essential thrombocythemia.
Fig. 2. Appearance of the right lumbal region of a patient with
essential thrombocythemia and livedo reticularis including 
reticulated purplish-blue patches, in part, with broken circular
segments (The arrowhead indicates the biopsy site).
Fig. 3. Appearance of a portion of hyalinized dermal blood 
vessels with a perivascular, moderately inflammatory, mainly 
lymphocytic infiltrate. In particular, the vessels of the deep 
dermis are hyalinized and occluded by intravascular thrombosis
(Hematoxylin-eosin stain, ×200 magnification).
and reticulated purplish-blue patches with broken circular 
segments on the lower extremities, hips, and lumbar 
region (right＞left; Fig. 2). The lesions on the bottom of 
the feet were extremely painful in warmth and during 
walking. Over a 1-year period, the patient had elevated 
thrombocytes with a mean±standard deviation of 671.166± 
20.0436/μl (range: 502.000∼1,045.000/μl). C-reactive 
protein and erythrocyte cell count was always normal, but 
leucocyte counts partly revealed slight leucocytosis. 
Lactate dehydrogenase was elevated at 343 U/L (normal 
range, 125∼235U/L). Further pathologies included protein 
S 59% (normal range, 73∼143%), factor VIII/C activity 
48% (normal range, 50∼150%), ristocetin-cofactor 4% 
(normal range, 50∼150%), von Willebrand-factor antigen 
26% (blood group non-0: 69∼179%), anti-phosphatidylserine 
IgG and IgM antibodies 51.3 U/ml and 23.3 U/ml, 
respectively (normally ＜15 U/ml), and positive smooth 
muscle autoantibody. Antinuclear antibodies and p- and 
c-anti-neutrophil cytoplasmic antibodies were within the 
normal ranges. Polymerase chain reaction analysis of 
bone morrow revealed a JAK2 gene mutation (codon 
V617F), and no BCR-ABL transcripts were found. Bone 
morrow aspirate and histology were consistent with an 
initial stage of ET. Skin biopsy from the right hip revealed 
lymphohistiocytic perivascular infiltrates and deep dermal 
obliterated vessels with fibrinoid necrosis (Fig. 3). Lymph 
node ultrasound, thoracic and abdomen computed tomo-
graphy, and cranial magnetic resonance tomography did 
not reveal remarkable findings. The patient was treated 
with aspirin (100 mg daily), which led to a immediate 
dramatic improvement of erythromelalgia. Furthermore, 
the patient was administered hydroxyurea (1,000 mg 
daily).
DISCUSSION
The discovery of the JAK2V617F mutation followed by the 
discovery of JAK2 exon 12, and MPLW515 and TET2 
mutations has completely modified the understanding, 
diagnosis, and management of the classic MPDs. JAK2V617F T Gambichler and R Matip 
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mutations are present in 90% of patients with polycy-
thaemia vera, 60% of patients with ET, and 50% of 
patients with myelofibrosis. The diagnostic utility of the 
MPL and TET2 mutations is limited by their relatively low 
mutational frequency. There is now strong evidence that 
these mutations are the oncogenic events that drive these 
disorders and are responsible for most biologic and 
clinical abnormalities. The number of JAK2V617F copies 
(homozygosity vs. heterozygosity) is important in explain-
ing how a single mutation can be associated with several 
disorders. However, it is still uncertain whether these 
mutations are sufficient to explain the full development, 
heterogeneity, and progression of MPDs, or if other 
genetic or epigenetic events are also necessary
1,2.
Patients with ET are at increased risk for arterial and 
venous thromboembolic events. Arterial ischemic complica-
tions occur in about 35% of patients with ET, in particular 
those with cardiovascular risk factors such as cigarette 
smoking. Non-atheromatous arterial thrombosis affects 
large and medium-sized vessels such as cerebral, limb, 
coronary, and digestive arteries. Moreover, juvenile 
myocardial infarction or rapid postangioplasty coronary 
thrombosis may reveal ET. Venous thrombosis is more 
common in polycytemia vera than in ET. Thrombo-
embolic events occur in about 25∼30% of the patients 
and account for one-third of deaths
1-3,8. Decreased levels 
of protein S, as observed in the present case, may be 
secondary to chronic clinically occult thrombosis occurr-
ing in ET
9. Apart from erythromelalgia and livedo 
reticularis, microvascular circulatory disturbances include 
Raynaud's phenomenon, acrocyanosis, blue toe synd-
rome, and cutaneous ulcers or necrotic purpura
1,6,7. As 
also true for the present case, the aforementioned cuta-
neous signs are frequently the first symptoms of ET and 
may precede the underlying myeloproliferative disorder 
by several months. Erythromelalgia is a rare condition of 
unknown etiology that results in intense, burning pain and 
redness, primarily of the feet, and, even more rarely, the 
hands. Most cases are idiopathic (primary erythromelalgia), 
while others occur secondary to medical conditions such 
as autoimmune diseases, neurological disorders, and 
MDS. Symptoms are episodic and can result in severe 
disability. Triggers, such as exposure to warmth, pressure, 
or exercise become apparent to those afflicted with this 
condition. If left untreated, erythromelalgia may progress 
towards persistent acrocyanosis and even peripheral 
gangrene
4,5 .
Another microvascular circulatory condition infrequently 
associated with ET is livedo reticularis (racemosa-type), 
which is characterized by a striking violaceous netlike 
patterning of the skin similar to the familiar livedo 
reticularis, from which it differs by its location (more 
generalized and widespread, found not only on the limbs, 
but also on the trunk and/or buttocks), its shape (irregular, 
broken, circular segments), and its biopsy results. Histo-
pathologically, only small-to-medium-size arteries of the 
dermis-subcutis boundary are involved in a stage-specific 
pattern in livedo reticularis (racemosa-type), particularly 
showing partial or complete occlusion of the lumen by a 
plug of lymphohistiocytic cells and fibrin. Livedo racemosa 
is the typical sign of Sneddon's syndrome and anti-
phospholipid syndrome
7. Interestingly, our patient had 
livedo reticularis associated with elevated antiphos-
pholipid antibodies highly suggesting an antiphospholipid 
syndrome. However, patients with ET may show auto-
immune epiphenomena, such as elevated antiphospholipid 
and/or antinuclear antibodies
10,11.
Hemorrhagic manifestations in ET are often limited to 
recurrent skin manifestations, such as subcutaneous hema-
tomas and epistaxis. Hemorrhagic complications are infre-
quently observed during the course of the condition when 
appropriate preventive measures are taken. Hemorrhagic 
symptoms are predominantly observed in patients with 
very high platelet counts
1-3. The hemorrhagic diathesis is 
not due to impaired platelet function, but rather to an 
acquired von Willebrand's disease
12, which was also 
found in the present case. In ET, acquired von Willebrand's 
disease is likely caused by proteolytic reduction of von 
Willebrand factor multimers. There is an inverse relation-
ship between von Willebrand factor levels and platelet 
counts. The von Willebrand factor large multimer 
deficiency appears at platelet counts of 1,000 to 1,500× 
10
9/L, and increases thereafter. Aspirin may unmask a 
latent bleeding diathesis and may result in severe 
hemorrhagic complications. It is, therefore, contraindicated 
in patients with bleeding history and a very high platelet 
count (in excess of 1,500×10
9/L leading to the acquisition 
of von Willebrand's deficiency)
1,12. We considered our 
patient at intermediate thrombohemorrhagic risk, given 
the presence of diabetes, a platelet count below 1,500× 
10
9/L, and age between 40 and 60 years
1,3. Because of this 
risk profile and acquired von Willebrand's disease, we 
initiated cytoreduction using hydroxyurea. 
In conclusion, the present case highlights the complex 
nature and diagnostic challenge of MDSs, such as ET, 
which can involve multiple organ systems and often 
shows a variety of microvascular complications, coagula-
tion anomalies, and autoimmune phenomena.
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